인수공통 감염병 치료 시장 : 치료법, 백신 유형, 진단법, 최종사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Zoonotic Disease Treatment Market is projected to grow by USD 88.27 billion at a CAGR of 9.12% by 2032.

Zoonotic disease treatment is moving from a reactive infectious disease category to a strategic One Health priority spanning human medicine, veterinary health, diagnostics, vaccines, antivirals, antimicrobials, immunotherapies, and surveillance-enabled care. The market is shaped by well-established epidemiological evidence: the WHO and CDC recognize that most known infectious diseases in people and a large share of emerging infectious diseases originate in animals, with spillover risks amplified by land-use change, livestock intensification, wildlife trade, climate variability, global travel, and urbanization.

Commercial demand is supported by recurring outbreaks of rabies, brucellosis, leptospirosis, avian influenza, dengue, chikungunya, plague, viral hemorrhagic fevers, and other zoonoses that require rapid diagnosis, appropriate therapeutics, post-exposure prophylaxis, infection control, and coordinated public health response. For industry leaders, the opportunity lies in building treatment portfolios that connect early detection, evidence-based clinical management, antimicrobial stewardship, vaccination, and animal-to-human risk reduction.

Transformative Shifts in the Treatment Landscape

The zoonotic disease treatment landscape is being transformed by the convergence of One Health policy, pandemic preparedness funding, genomic surveillance, and decentralized diagnostics. Governments and multilateral organizations are prioritizing integrated surveillance across humans, animals, food systems, and the environment, which is changing procurement requirements and encouraging solutions that can work across hospitals, laboratories, farms, and field-response settings.

Another major shift is the move from broad, empiric intervention toward pathogen-specific and resistance-aware treatment decisions. Antimicrobial resistance, vaccine hesitancy, cold-chain limitations, and uneven access to diagnostics are forcing manufacturers and healthcare systems to prove clinical value, operational feasibility, and cost-effectiveness. Organizations that pair therapies with rapid tests, real-world evidence, pharmacovigilance, and outbreak response services are better positioned to win institutional trust.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing zoonotic disease treatment by improving outbreak intelligence, differential diagnosis, drug discovery, clinical trial design, supply forecasting, and pharmacovigilance. AI models can integrate signals from genomic sequencing, syndromic surveillance, veterinary alerts, climate data, mobility patterns, and electronic health records to identify risk clusters and support faster triage during outbreaks.

The cumulative impact is strongest when AI is governed by validated datasets, transparent model performance, clinical oversight, and privacy-preserving data sharing. In treatment development, machine learning can accelerate target identification, repurposing screens, protein-structure analysis, and adverse event detection; however, adoption depends on regulatory-grade evidence, bias control, cybersecurity, and interoperability with public health systems.

Key Regional Insights

Asia-Pacific is a critical growth region due to high population density, large livestock systems, biodiversity hotspots, and recurring exposure to vector-borne and foodborne zoonoses. China, India, Japan, South Korea, Australia, and ASEAN countries are investing in surveillance, vaccine capacity, and rapid diagnostics, while treatment access varies widely between advanced urban hospitals and rural outbreak settings. North America benefits from strong public health infrastructure, advanced hospital systems, veterinary surveillance, and active biodefense and pandemic preparedness programs, supporting demand for validated diagnostics, post-exposure prophylaxis, vaccines, antivirals, and antimicrobial stewardship tools.

Latin America faces persistent burdens from arboviruses, leptospirosis, rabies risk, and zoonotic parasitic diseases, with Brazil and Mexico serving as important demand centers for diagnostics, vaccines, and outbreak-ready therapeutics. Europe is shaped by coordinated health security frameworks, antimicrobial stewardship, veterinary regulation, cross-border surveillance, and strong research networks, which encourage evidence-based adoption and high standards for clinical validation.

The Middle East is increasing preparedness due to MERS-CoV experience, pilgrimage-related health security, imported infection risk, and GCC investment in advanced healthcare infrastructure. Africa carries a disproportionate burden for rabies deaths, viral hemorrhagic fever response, and neglected zoonoses, creating urgent need for affordable diagnostics, post-exposure prophylaxis, cold-chain resilience, trained frontline capacity, and regional manufacturing partnerships.

Key Group Insights

ASEAN markets are prioritizing cross-border surveillance, avian influenza readiness, dengue-related care pathways, rabies control, and scalable point-of-care testing as trade, tourism, wildlife interfaces, and dense livestock production increase spillover concerns. The GCC is emphasizing health security, hospital modernization, infection prevention, and regional preparedness after experience with MERS-CoV, making it receptive to high-quality diagnostics, infection control technologies, and stockpile-ready medical countermeasures.

The European Union has a mature regulatory and research environment supported by coordinated health emergency response, veterinary oversight, antimicrobial stewardship, pharmacovigilance, and cross-border data sharing. BRICS countries combine large disease burdens with expanding pharmaceutical manufacturing capacity, rising diagnostic capability, and strategic public health investment, positioning them as important participants in zoonotic disease treatment access, production, and outbreak response.

G7 markets influence global procurement standards through R&D funding, regulatory expectations, preparedness finance, vaccine policy, and support for international health security initiatives. NATO members increasingly view zoonotic outbreaks through a biosecurity and resilience lens that values surveillance, medical countermeasures, interoperable response systems, protected supply chains, and continuity of care during health emergencies.

Key Country Insights

The United States leads in biomedical innovation, pandemic preparedness funding, advanced diagnostics, genomic surveillance, and regulatory pathways for medical countermeasures, while Canada emphasizes integrated public health, zoonotic surveillance, vaccination policy, and antimicrobial stewardship. Mexico and Brazil face significant vector-borne, foodborne, and livestock-associated risks, creating demand for accessible diagnostics, vaccines, post-exposure prophylaxis, and field-deployable treatment support.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong clinical research, public health capacity, veterinary surveillance, and antimicrobial stewardship programs, with Germany and France especially important for pharmaceutical and diagnostics innovation. Russia has substantial scientific capacity and zoonotic monitoring needs across vast ecosystems, while China and India represent large-scale opportunities due to population size, livestock exposure, manufacturing capabilities, emerging diagnostic capacity, and government investment in health security.

Japan, South Korea, and Australia are advanced markets with strong quality expectations, rapid diagnostic adoption, robust public health systems, and regional preparedness roles. Australia's biosecurity model and zoonotic surveillance capabilities are particularly relevant to animal-human interface management, while Japan and South Korea support innovation through sophisticated healthcare systems, high standards for clinical validation, and strong infectious disease response infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should align product strategy with One Health procurement by demonstrating value across human health, animal health, and public health response. Priority actions include pairing therapies with rapid diagnostics, investing in pathogen-agnostic platforms, building evidence for use in outbreak conditions, and designing products that remain effective in low-resource and cold-chain-constrained environments.

Organizations should strengthen partnerships with public health agencies, veterinary networks, academic laboratories, and regional manufacturers to improve access and trust. Commercial success will depend on antimicrobial stewardship, transparent clinical evidence, flexible supply chains, regulatory preparedness, and the ability to support governments with surveillance-linked treatment pathways rather than isolated products.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in authoritative public sources, including WHO, CDC, WOAH, FAO, national public health agencies, regulatory bodies, peer-reviewed literature, and publicly available government preparedness frameworks. The analysis synthesizes epidemiological burden, policy direction, technology adoption, regional readiness, and treatment access factors.

The methodology emphasizes triangulation across clinical, veterinary, regulatory, and market indicators to identify durable demand signals while avoiding unsupported market claims. Insights are evaluated through a One Health lens, considering disease burden, healthcare infrastructure, diagnostic capacity, vaccine and therapeutic availability, antimicrobial resistance, pharmacovigilance, and outbreak response readiness.

Conclusion

Zoonotic disease treatment is becoming a core component of global health security, driven by recurring outbreaks, antimicrobial resistance, climate-linked vector shifts, ecosystem disruption, and the need for faster, more coordinated response systems. The most resilient market participants will move beyond single-product strategies and build integrated solutions that connect diagnostics, therapeutics, vaccines, surveillance, and access.

As governments and healthcare systems invest in preparedness, organizations that can deliver validated, scalable, and regionally adaptable treatment solutions will be best positioned to capture growth. The future of the market belongs to stakeholders that combine scientific rigor, One Health collaboration, digital intelligence, regulatory readiness, and equitable deployment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Zoonotic Disease Treatment Market, by Therapeutics

• 7.1. Antibiotics
  • 7.1.1. Beta-Lactams
  • 7.1.2. Macrolides
  • 7.1.3. Tetracyclines
• 7.2. Antifungals
  • 7.2.1. Azoles
  • 7.2.2. Polyenes
• 7.3. Antiparasitics
  • 7.3.1. Anthelmintics
  • 7.3.2. Antiprotozoals
• 7.4. Antivirals
  • 7.4.1. mAb
  • 7.4.2. Nucleoside
  • 7.4.3. Protease Inhibitors

8. Zoonotic Disease Treatment Market, by Vaccine Type

• 8.1. Preventive Vaccines
  • 8.1.1. Attenuated
  • 8.1.2. Conjugate
  • 8.1.3. mRNA
  • 8.1.4. Recombinant
• 8.2. Therapeutic Vaccines
  • 8.2.1. Attenuated
  • 8.2.2. Conjugate
  • 8.2.3. mRNA
  • 8.2.4. Recombinant

9. Zoonotic Disease Treatment Market, by Diagnostics

• 9.1. Imaging
  • 9.1.1. Radiography
  • 9.1.2. Ultrasound
• 9.2. Molecular Diagnostics
  • 9.2.1. Next Generation Sequencing
  • 9.2.2. PCR
• 9.3. Point Of Care
• 9.4. Serology
  • 9.4.1. ELISA
  • 9.4.2. Rapid Test

10. Zoonotic Disease Treatment Market, by End User

• 10.1. Hospitals
• 10.2. Clinics
• 10.3. Veterinary Centers
• 10.4. Research Institutes

11. Zoonotic Disease Treatment Market, by Distribution Channel

• 11.1. Online
• 11.2. Offline

12. Zoonotic Disease Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Zoonotic Disease Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Zoonotic Disease Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AdvaCare Pharma
• 16.2. Bharat Biotech International Ltd.
• 16.3. Bimeda
• 16.4. Bio-Med Pvt. Ltd.
• 16.5. Boehringer Ingelheim GmbH
• 16.6. Ceva Sante Animale
• 16.7. Chengda Biotechnology Co., Ltd.
• 16.8. Dechra Pharmaceuticals PLC
• 16.9. ECO Animal Health Group Plc
• 16.10. Elanco Animal Health Incorporated
• 16.11. Endovac Animal Health
• 16.12. Hester Biosciences Ltd.
• 16.13. Huvepharma
• 16.14. IDEXX Laboratories, Inc.
• 16.15. Inovet Group
• 16.16. Intas Pharmaceuticals Ltd.
• 16.17. Kyoritsu Seiyaku Corporation
• 16.18. Meiji Holdings Co., Ltd.
• 16.19. Merck & Co., Inc.
• 16.20. Norbrook Laboratories
• 16.21. Phibro Animal Health Corporation
• 16.22. SeQuent Scientific Ltd.
• 16.23. Vetoquinol S.A.
• 16.24. Zoetis Inc.
• 16.25. Zydus Lifesciences Limited